google.com, pub-6550880898423263, DIRECT, f08c47fec0942fa0
An anti-cancer drug originally developed for use in people is in the hands of a veterinary pharmaceutical startup that aims to make it available for dogs within two years.
Veterinary Emerging Technologies Development Corporation, or VetDC, announced recently that it has raised $1.5 million to develop an agent it calls VDC-1101 into what could be the first drug specifically designed to combat canine lymphoma.
Lymphoma is one of the most common cancers in dogs and highly deadly.
“Anything new that has the potential to enhance quality of life and improve the disease-free interval is a blessing,” said Dr. Greg Ogilvie, an oncologist and director of the Angel Care Cancer Center at California Veterinary Specialists in Carlsbad.
Ogilvie, who is not associated with VetDC, said he sees about 300 cases of lymphoma per year. “Lymphoma is not just one disease but many different diseases,” he explained. “Without therapy, the average dog lives one or two or three months. If treated appropriately, they have a chance of doing well for up to a year.”
Only two cancer therapies are available in the United States specifically for use in dogs, and neither combats lymphoma. Palladia in 2009 became the first canine cancer drug to be approved by the U.S. Food and Drug Administration (FDA). It is designed to treat skin-based mast cell tumors.
In 2010, the U.S. Department of Agriculture granted full licensure for Oncept, a DNA vaccine to treat oral melanoma in dogs.
All other cancer drugs used in veterinary medicine originally were developed for use in humans and are not approved for use in other animals, according to the FDA. Although not specifically approved for use in veterinary patients, the “extra-label” use of human oncology medicines is permitted under the Animal Medicinal Drug Use Clarification Act of 1994.
In a twist on the theme, VetDC aspires to develop for veterinary use treatments, tests and devices researched for use in people but abandoned, according to a company profile in Genetic Engineering & Biotechnology News .
VetDC was launched in 2010. A year later, it acquired a license from Gilead Sciences, Inc., for GS-9219, an investigational molecule that selectively targets and kills cancerous lymphoma cells. VetDC renamed the agent VDC-1101.
Steven J. Roy, president and CEO of VetDC, said in an interview that Gilead stopped pursuing development because the drug didn't meet the company’s expectations for human use.
"They did a large amount of testing in dogs with lymphoma before going into human trials,” Roy said. “They demonstrated an 80 percent response rate and showed tremendous promise, but they were a human company and not looking to make a veterinary medicine."
He added: "Vets hope to manage cancer like they do on human side, and treat it like a chronic disease where you can keep cancer at bay much longer. Hopefully, we can manage this in a way to give a pet four or five years instead of several months."
Roy said he hopes the drug will be available within a couple of years.
Ogilvie, the clinical oncologist, said data on the prospective drug are encouraging. “We hope it will result in survival times suggested by the manufacturer. They suggest a 50 percent increase in survival. We are really hoping that will be true,” he said. “It's just going to ... take a while to get a good, clear understanding of the true benefit of it.”
Source: http://news.vin.com/VINNews.aspx?articleId=25533
google.com, pub-6550880898423263, DIRECT, f08c47fec0942fa0
Please LIKE , Tweet , +1 and Share if you like this article...
3 comments:
Hi. Working in a non profit animal cancern non profit, we field thousands of calls from frantic pet owners whose beloved dogs have been diagnosed with lymphoma. It is indeed heartwrenching to hear their stories.
I am delighted that your company has developed a new drug but quickly add that there is a treatment available that has shown great success: T Cell Infusions. Studies between MD Anderson and clinical trials at Texas A&M proved successful. Sadly, it is not available for the public at this time. Is it because it is in direct conflict with pharmaceuticals and if so, is this fair to dogs who could benefit?
It is my understanding that a drug was manufactured at a pharma company with little success as T Cell Infusions showed much more promise. It seems as if it is all about money. What a sad state of affairs.
I would love to learn more about T-Cell Infusion. It breaks my heart to see pharmaceutical companies along with individuals trying to profit from desperate and heart broken pet owners of their precious dogs suffering from Lymphoma or any terminal disease. How low can people step!!
This is the precise weblog for anybody who needs to seek out out about this topic. You notice so much its almost arduous to argue with you. You positively put a brand new spin on a subject that's been written about for years. Nice stuff, simply nice!
Post a Comment